Effects of the matricellular protein SPARC on human retinal pigment epithelial cell behavior

Molecular Vision

Volumn 9, Issue , 2003, Pages 87-92

  Hagan, Suzanne ^a   Hiscott, Paul ^a   Sheridan, Carl Michael ^a   Wong, David ^a   Grierson, Ian ^a   McGalliard, James ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; FIBRONECTIN; PROTEIN SPARC; SCLEROPROTEIN; UNCLASSIFIED DRUG; OSTEONECTIN;

ADULT; ARTICLE; CELL CULTURE; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFANT; MALE; PIGMENT EPITHELIUM; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE; VITREORETINOPATHY; CELL DIVISION; CELL MOTION; CYTOLOGY; DRUG EFFECT; METABOLISM;

ADULT; CELL DIVISION; CELL MOVEMENT; CELLS, CULTURED; COLLAGEN; EXTRACELLULAR MATRIX; FEMALE; FIBRONECTINS; HUMANS; INFANT; MALE; OSTEONECTIN; PIGMENT EPITHELIUM OF EYE;

EID: 0037464186     PISSN: 10900535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Bornstein P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J Cell Biol 1995; 130:503-6.
2. Murphy-Ullrich JE. The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state? J Clin Invest 2001; 107:785-90.
3. Sage EH, Bornstein P. Extracellular proteins that modulate cell-matrix interactions. SPARC, tenascin, and thrombospondin. J Biol Chem 1991; 266:14831-4.
4. Chiquet-Ehrismann R. Anti-adhesive molecules of the extracellular matrix. Curr Opin Cell Biol 1991; 3:800-4.
5. Dziadek M, Paulsson M, Aumailley M, Timpl R. Purification and tissue distribution of a small protein (BM-40) extracted from a basement membrane tumor. Eur J Biochem 1986; 161:455-64.
6. Termine JD, Kleinman HK, Whitson SW, Conn KM, McGarvey ML, Martin GR. Osteonectin, a bone-specific protein linking mineral to collagen. Cell 1981; 26:99-105.
7. Bradshaw AD, Francki A, Motamed K, Howe C, Sage EH. Primary mesenchymal cells isolated from SPARC-null mice exhibit altered morphology and rates of proliferation. Mol Biol Cell 1999; 10:1569-79.
8. Hasselaar P, Sage EH. SPARC antagonizes the effect of basic fibroblast growth factor on the migration of bovine aortic endothelial cells. J Cell Biochem 1992; 49:272-83.
9. Bradshaw AD, Sage EH. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 2001; 107:1049-54.
10. Machemer R, Aaberg TM, Freeman HM, Irvine AR, Lean JS, Michels RM. An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol 1991; 112:159-65.
11. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 1983; 90:121-5.
12. Hiscott P, Larkin G, Robey HL, Orr G, Grierson I. Thrombospondin as a component of the extracellular matrix of epiretinal membranes: comparisons with cellular fibronectin. Eye 1992; 6:566-9.
13. Hiscott P, Sheridan C, Magee RM, Grierson I. Matrix and the retinal pigment epithelium in proliferative retinal disease. Prog Retin Eye Res 1999; 18:167-90.
14. Carron JA, Hiscott P, Hagan S, Sheridan CM, Magee R, Gallagher JA. Cultured human retinal pigment epithelial cells differentially express thrombospondin-1, -2, -3, and -4. Int J Biochem Cell Biol 2000; 32:1137-42.
15. Magee RM, Hagan S, Hiscott PS, Sheridan CM, Carron JA, McGalliard J, Grierson I. Synthesis of osteonectin by human retinal pigment epithelial cells is modulated by cell density. Invest Ophthalmol Vis Sci 2000; 41:22707-11.
16. Sheridan C, Magee R, Hiscott P, Wong D, McGalliard J, Grierson, I. The role of thrombospondin-1 and osteonectin during RPE cell migration in proliferative vitreoretinopathy. Curr Eye Res. In press 2003.
17. Hiscott P, Hagan S, Heathcote L, Sheridan CM, Groenewald CP, Grierson I, Wong D, Paraoan L. Pathobiology of epiretinal and subretinal membranes: possible roles for the matricellular proteins thrombospondin 1 and osteonectin (SPARC). Eye 2002; 16:393-403.
18. Edwards RB. Culture of mammalian retinal pigment epithelium and neural retina. Methods Enzymol 1982; 81:39-43.
19. Boulton ME, Marshall J, Mellerio J. Human retinal pigment epithelial cells in tissue culture: a means of studying inherited retinal diseases. Birth Defects Orig Artic Ser 1982; 18:101-18.
20. Robey HL, Hiscott PS, Grierson I. Cytokeratins and relationship to retinal pigment epithelial cell behaviour. J Cell Sci 1992; 102:329-40.
21. Falk W, Goodwin RH Jr, Leonard EJ. A 48-well micro chemotaxis assembly for rapid and accurate measurement of leukocyte migration. J Immunol Methods 1980; 33:239-47.
22. Campochiaro PA, Jerdan JA, Glaser BM. Serum contains chemoattractants for human retinal pigment epithelial cells. Arch Ophthalmol 1984; 102:1830-3.
23. Mazure A, Grierson I. In vitro studies of the contractility of cell types involved in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1992; 33:3407-16.
24. Funk SE, Sage EH. Differential effects of SPARC and cationic SPARC peptides on DNA synthesis by endothelial cells and fibroblasts. J Cell Physiol 1993; 154:53-63.
25. Choudhury P, Chen W, Hunt RC. Production of platelet-derived growth factor by interleukin-1 beta and transforming growth factor-beta-stimulated retinal pigment epithelial cells leads to contraction of collagen gels. Invest Ophthalmol Vis Sci 1997; 38:824-33.
26. Docherty RJ, Forrester JV, Lackie JM. Type I collagen permits invasive behaviour by retinal pigmented epithelial cells in vitro. J Cell Sci 1987; 87:399-409.
27. Guidry C, McFarland RJ, Morris R, Witherspoon CD, Hook M. Collagen gel contraction by cells associated with proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1992; 33:2429-35.
28. Raymond MC, Thompson JT. RPE-mediated collagen gel contraction. Inhibition by colchicine and stimulation by TGF-beta. Invest Ophthalmol Vis Sci 1990; 31:1079-86.
29. Sheridan CM, Occleston NL, Hiscott P, Kon CH, Khaw PT, Grierson I. Matrix metalloproteinases: a role in the contraction of vitreo-retinal scar tissue. Am J Pathol 2001; 159:1555-66.
30. Grierson I, Mazure A, Hogg P, Hiscott P, Sheridan C, Wong D. Non-vascular vitreoretinopathy: the cells and the cellular basis of contraction. Eye 1996; 10:671-84.
31. Jerdan JA, Pepose JS, Michels RG, Hayashi H, de Bustros S, Sebag M, Glaser BM. Proliferative vitreoretinopathy membranes. An immunohistochemical study. Ophthalmology 1989; 96:801-10.
32. Laqua H. Collagen formation by periretinal cellular membranes. Dev Ophthalmol 1981; 2:396-406.
33. Hiscott P, Morino I, Alexander R, Grierson I, Gregor Z. Cellular components of subretinal membranes in proliferative vitroretinopathy. Eye 1989; 3:606-10.
34. Sasaki T, Gohring W, Mann K, Maurer P, Hohenester E, Knauper V, Murphy G, Timpl R. Limited cleavage of extracellular matrix protein BM-40 by matrix metalloproteinases increases its affinity for collagens. J Biol Chem 1997; 272:9237-43.
35. Sasaki T, Miosge N, Timpl R. Immunochemical and tissue analysis of protease generated neoepitopes of BM-40 (osteonectin, SPARC) which are correlated to a higher affinity binding to collagens. Matrix Biol 1999; 18:499-508.
36. Brekken RA, Sage EH. SPARC, a matricellular protein at the crossroads of cell-matrix. Matrix Biol 2000; 19:569-80.
37. Iruela-Arispe ML, Vernon RB, Wu H, Jaenisch R, Sage EH. Type I collagen-deficient Mov-13 mice do not retain SPARC in the extracellular matrix: implications for fibroblast function. Dev Dyn 1996; 207:171-83.
38. Sawhney RS. Identification of SPARC in the anterior lens capsule and its expression by lens epithelial cells. Exp Eye Res 1995; 61:645-8.
39. Gilbert RE, Cox AJ, Kelly DJ, Wilkinson-Berka JL, Sage EH, Jerums G, Cooper ME. Localization of secreted protein acidic and rich in cysteine (SPARC) expression in the rat eye. Connect Tissue Res 1999; 40:295-303.
40. Kim SY, Ondhia N, Vidgen D, Malaval L, Ringuette M, Kalnins VI. Spatiotemporal distribution of SPARC/osteonectin in developing and mature chicken retina. Exp Eye Res 1997; 65:681-9.
41. Yan Q, Sage EH, Hendrickson AE. SPARC is expressed by ganglion cells and astrocytes in bovine retina. J Histochem Cytochem 1998; 46:3-10.
42. Rodriguez IR, Moreira EF, Bok D, Kantarow M. Osteonectin/SPARC secreted by RPE and localized to the outer plexiform layer of the monkey retina. Invest Ophthalmol Vis Sci 2000; 41:2438-44.
43. Gilmour DT, Lyon GJ, Carlton MB, Sanes JR, Cunningham JM, Anderson JR, Hogan BL, Evans MJ, Colledge WH. Mice deficient for the secreted glycoprotein SPARC/osteonectin/BM40 develop normally but show severe age-onset cataract formation and disruption of the lens. EMBO J 1998; 17:1860-70.
44. Norose K, Clark JI, Syed NA, Basu A, Heber-Katz E, Sage EH, Howe CC. SPARC deficiency leads to early-onset cataractogenesis. Invest Ophthalmol Vis Sci 1998; 39:2674-80.
45. Raines EW, Lane TF, Iruela-Arispe ML, Ross R, Sage EH. The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. Proc Natl Acad Sci U S A 1992; 89:1281-5.
46. Francki A, Bradshaw AD, Bassuk JA, Howe CC, Couser WG, Sage EH. SPARC regulates the expression of collagen type I and transforming growth factor-beta1 in mesangial cells. J Biol Chem 1999; 274:32145-52.
47. Sage EH, Bassuk JA, Yost JC, Folkman MJ, Lane TF. Inhibition of endothelial cell proliferation by SPARC is mediated through a Ca(2+)-binding EF-hand sequence. J Cell Biochem 1995; 57:127-40.
48. Kupprion C, Motamed K, Sage EH. SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J Biol Chem 1998; 273:29635-40.